# Intellia Therapeutics

Type: Company (NTLA)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/intellia-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/intellia-therapeutics

## Timeline

- **2026-02-26**: Functional Cure Declared — Medical reports confirm the patient is effectively cured of the rare disease.
- **2025-06-10**: Long-term Follow-up — B.C. patient reports zero attacks one year after single dose.
- **2024-03-15**: Phase 1/2 Results — Intellia releases early data showing significant reduction in HAE attacks.

## Recent coverage (2 stories)

### Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth
2026-02-26 22:32:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Full story: https://getbiobrief.com/story/q4-2025-biotech-earnings-analysis

### B.C. Man Cured of Rare Disease in Landmark CRISPR Gene-Editing Success
2026-02-26 11:31:59 · Sentiment: Strongly positive · Impact: 9/10 · Sources: 2

A British Columbia man has been declared functionally cured of Hereditary Angioedema (HAE) following a world-first in-vivo CRISPR gene-editing treatment. The success of Intellia Therapeutics' NTLA-2002 therapy marks a pivotal shift from chronic disease management to permanent genetic correction.
Full story: https://getbiobrief.com/story/bc-man-cured-rare-disease-gene-editing-landmark

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.